サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1439672

尿路結石管理機器 - 世界市場の考察、競合情勢、市場予測（2030年）

Urolithiasis Management Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日: 受注後更新 | 発行: DelveInsight | ページ情報: 英文 150 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
尿路結石管理機器 - 世界市場の考察、競合情勢、市場予測（2030年）
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の尿路結石管理機器の市場規模は、2023年に15億3,108万米ドル、2030年までに19億6,312万米ドルに達し、2024年～2030年の予測期間にCAGRで4.27%の成長が見込まれます。市場は、尿路結石または腎結石の有病率の上昇により、プラス成長を示しています。さらに、腎結石発症の危険因子である肥満などの座りがちなライフスタイル、製品設計の革新、末期腎不全のリスクの増加、老年人口の増加、処置に対する意識の高まりなどが、2024年～2030年の予測期間における市場の成長に寄与しています。

尿路結石管理機器の市場力学

尿路結石管理機器市場は、さまざまな理由により製品需要が増加しています。主な要因は、世界中での尿路結石の有病率の上昇などです。

European Association of Urology（2019）によると、尿路結石の有病率は1％～20％と幅があり、カナダ、スウェーデン、米国などの生活水準の高い国では、腎結石の有病率がかなり高い（10％超）です。

British Association of Urological Surgeons（2022）によれば、腎結石は一般的です。CTスキャンを受けた患者は8％の確率で腎結石に罹患し、その罹患率は20世紀初頭から着実に増加しています。さらに、11人に1人（9％）が生涯のうちに結石状を起こします。男性のほうが女性よりやや罹患しやすいです。あらゆる年齢層の患者が結石を患いますが、最初の結石のピークとなる年齢は45歳前後です。

National Kidney Foundation（2022）によると、毎年50万人以上が腎結石の問題で救急外来を受診しています。

さらに、アルコールの過剰摂取や水分摂取の減少など、座りがちなライフスタイルの増加も腎結石の発症につながる可能性があります。さらに、食生活の乱れや運動不足などの座りがちなライフスタイルにより、腎結石発症の高危険因子である肥満の負担が増加していることも、尿路結石管理機器市場の成長に寄与する可能性があります。

世界保健機関（WHO）の2022年のデータによると、2016年の世界の肥満人口は約6億5,000万人でした。また、さまざまな研究によると、肥満の人々は尿酸結石やシュウ酸カルシウム結石をより多く発症します。

また、老年人口は腎結石が形成されやすく、末期腎不全のリスクが高まりまます。World Population Prospects 2019によると、2019年の65歳以上の高齢者は世界で7億300万人です。したがって、老年人口が増加するにつれて、尿路結石の有病率が増加し、結果として尿路結石管理機器の需要を押し上げ、それが世界の尿路結石管理機器市場の成長を促進します。

しかし、尿管鏡機器の高いコストや内出血中の失血のような術後合併症といった特定の要因は、尿路結石管理機器市場の成長の一定の抑制要因となる可能性があります。

COVID-19パンデミックの発生は、救急外来受診の大幅な減少を引き起こしました。さらに、外来診療の予約に遅れが生じ、バーチャル診療や電話診療へのニーズが高まっています。院内の病床数、麻酔や処置の枠、医療従事者の不足により、これらの変化は治療の大幅な滞りを生み、世界の尿路結石管理機器市場にマイナスの影響を与えました。

尿路結石管理機器市場のセグメント分析

尿路結石管理機器市場の治療セグメントでは、体外衝撃波結石破砕機（ESWL）が予測期間（2024年～2030年）に市場で高いシェアを占める見込みです。これは、これらの機器に関連する特定の機能によるものと考えられます。

この製品セグメントの高い市場シェアは、これらの機器を採用する患者の増加と、迅速な治療によるものと考えられます。ESWLの主な利点は、結石の治療に皮膚の切開や侵襲的な手術機器の使用を伴わないため、治療が完全に非侵襲であることです。代わりに衝撃波を利用して結石を細かく砕き、尿管を通って膀胱から排出します。

当レポートでは、世界の尿路結石管理機器市場について調査分析し、市場規模と予測、促進要因と課題、企業と製品のプロファイルなどを提供しています。

目次

第1章 尿路結石管理機器市場レポートのイントロダクション

第2章 尿路結石管理機器市場のエグゼクティブサマリー

  • 調査範囲
  • 市場の概要
  • 競合の評価

第3章 規制と特許の分析

  • 米国
  • 欧州
  • 日本
  • 中国

第4章 尿路結石管理機器市場の主な要因の分析

  • 尿路結石管理機器市場の促進要因
    • 尿路結石または腎結石の有病率の上昇
    • 腎結石発症の危険因子としての座りがちなライフスタイル
    • 製品設計の革新
    • 末期腎不全のリスクの増加
    • 老年人口の増加
  • 尿路結石管理機器市場の抑制要因と課題
    • 尿管鏡機器の高いコスト
    • 術後の合併症
  • 尿路結石管理機器市場の機会
    • 先進の機器へのニーズ
    • 単回使用尿管鏡の機会の拡大

第5章 尿路結石管理機器市場のポーターのファイブフォース分析

第6章 尿路結石管理機器市場に対するCOVID-19の影響分析

第7章 尿路結石管理機器市場のレイアウト

  • タイプ別
    • 診断
    • 治療
  • エンドユーザー別
    • 病院
    • 外来手術センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • その他の地域

第8章 尿路結石管理機器市場：世界の企業シェア分析 - 主要3～5社

第9章 尿路結石管理機器市場の企業と製品のプロファイル

  • Boston Scientific Corporation
  • EMS Urology
  • Advin Health Care
  • Inceler Medikal Co. Ltd.
  • Walz Elektronik GmbH
  • DirexGroup
  • Medispec Ltd.
  • Richard Wolf GmbH
  • STORZ MEDICAL AG
  • Olympus
  • General Electric Company (GE Healthcare)
  • ESAOTE SPA
  • Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
  • BK Medical Holding Company, Inc.
  • Hitachi Medical Systems
  • Laborie
  • DRAMINSKI S. A.
  • ACE Medical Devices Pvt. Ltd.
  • Siemens Healthcare Private Limited
  • Vimex Sp. z o.o.

第10章 KOLの見解

第11章 プロジェクトのアプローチ

第12章 DelveInsightについて

第13章 免責事項とお問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Urolithiasis Management Devices Market in Global (2021-2030)
  • Table 4: Urolithiasis Management Devices Market in Global by Diagnostics (2021-2030)
  • Table 5: Urolithiasis Management Devices Market in Global by Treatment (2021-2030)
  • Table 6: Urolithiasis Management Devices Market in Global by End User (2021-2030)
  • Table 7: Urolithiasis Management Devices Market in Global by Geography (2021-2030)
  • Table 8: Urolithiasis Management Devices Market in North America (2021-2030)
  • Table 9: Urolithiasis Management Devices Market in North America by Country (2021-2030)
  • Table 10: Urolithiasis Management Devices Market in the US (2021-2030)
  • Table 11: Urolithiasis Management Devices Market in Canada (2021-2030)
  • Table 12: Urolithiasis Management Devices Market in Mexico (2021-2030)
  • Table 13: Urolithiasis Management Devices Market in Europe (2021-2030)
  • Table 14: Urolithiasis Management Devices Market in Europe by Country (2021-2030)
  • Table 15: Urolithiasis Management Devices Market in France (2021-2030)
  • Table 16: Urolithiasis Management Devices Market in Germany (2021-2030)
  • Table 17: Urolithiasis Management Devices Market in the United Kingdom (2021-2030)
  • Table 18: Urolithiasis Management Devices Market in Italy (2021-2030)
  • Table 19: Urolithiasis Management Devices Market in Spain (2021-2030)
  • Table 20: Urolithiasis Management Devices Market in Russia (2021-2030)
  • Table 21: Urolithiasis Management Devices Market in Rest of Europe (2021-2030)
  • Table 22: Urolithiasis Management Devices Market in APAC (2021-2030)
  • Table 23: Urolithiasis Management Devices Market in APAC by Country (2021-2030)
  • Table 24: Urolithiasis Management Devices Market in China (2021-2030)
  • Table 25: Urolithiasis Management Devices Market in Japan (2021-2030)
  • Table 26: Urolithiasis Management Devices Market in India (2021-2030)
  • Table 27: Urolithiasis Management Devices Market in Australia (2021-2030)
  • Table 28: Urolithiasis Management Devices Market in South Korea (2021-2030)
  • Table 29: Urolithiasis Management Devices Market in Rest of APAC (2021-2030)
  • Table 30: Urolithiasis Management Devices Market in Rest of World (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Urolithiasis Management Devices Market in Global (2021-2030)
  • Figure 4: Urolithiasis Management Devices Market in Global by Diagnostics (2021-2030)
  • Figure 5: Urolithiasis Management Devices Market in Global by Treatment (2021-2030)
  • Figure 6: Urolithiasis Management Devices Market in Global by End User (2021-2030)
  • Figure 7: Urolithiasis Management Devices Market in Global by Geography (2021-2030)
  • Figure 8: Urolithiasis Management Devices Market in North America (2021-2030)
  • Figure 9: Urolithiasis Management Devices Market in North America by Country (2021-2030)
  • Figure 10: Urolithiasis Management Devices Market in the US (2021-2030)
  • Figure 11: Urolithiasis Management Devices Market in Canada (2021-2030)
  • Figure 12: Urolithiasis Management Devices Market in Mexico (2021-2030)
  • Figure 13: Urolithiasis Management Devices Market in Europe (2021-2030)
  • Figure 14: Urolithiasis Management Devices Market in Europe by Country (2021-2030)
  • Figure 15: Urolithiasis Management Devices Market in France (2021-2030)
  • Figure 16: Urolithiasis Management Devices Market in Germany (2021-2030)
  • Figure 17: Urolithiasis Management Devices Market in the United Kingdom (2021-2030)
  • Figure 18: Urolithiasis Management Devices Market in Italy (2021-2030)
  • Figure 19: Urolithiasis Management Devices Market in Spain (2021-2030)
  • Figure 20: Urolithiasis Management Devices Market in Russia (2021-2030)
  • Figure 21: Urolithiasis Management Devices Market in Rest of Europe (2021-2030)
  • Figure 22: Urolithiasis Management Devices Market in APAC (2021-2030)
  • Figure 23: Urolithiasis Management Devices Market in APAC by Country (2021-2030)
  • Figure 24: Urolithiasis Management Devices Market in China (2021-2030)
  • Figure 25: Urolithiasis Management Devices Market in Japan (2021-2030)
  • Figure 26: Urolithiasis Management Devices Market in India (2021-2030)
  • Figure 27: Urolithiasis Management Devices Market in Australia (2021-2030)
  • Figure 28: Urolithiasis Management Devices Market in South Korea (2021-2030)
  • Figure 29: Urolithiasis Management Devices Market in Rest of APAC (2021-2030)
  • Figure 30: Urolithiasis Management Devices Market in Rest of World (2021-2030)
  • Figure 31: Market Drivers
  • Figure 32: Market Barriers
  • Figure 33: Marker Opportunities
  • Figure 34: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0512

Urolithiasis Management Devices Market By Type (Diagnostics [X-Ray, Computed Tomography, Ultrasound, Others], Treatment [Shock Wave Lithotripters {Intracorporeal, Extracorporeal}, Ureteroscopes {Semi-Rigid, Flexible}, Stone Retrieval Devices, Others], By End-User (Hospitals, Ambulatory Surgical Centers, Others), by geography is expected to grow at a steady CAGR forecast till 2030 owing to rising prevalence of urolithiasis and sedentary lifestyle

The global urolithiasis management devices market was valued at USD 1,531.08 million in 2023, growing at a CAGR of 4.27% during the forecast period from 2024 to 2030 to reach USD 1,963.12 million by 2030. The Urolithiasis Management Devices market is witnessing positive growth owing to the rising prevalence of urolithiasis or nephrolithiasis. In addition, sedentary lifestyle such as obesity which is a risk factor for the development of kidney stones, innovation in product design, increased risk of end-stage renal failure, growing geriatric population, and intensifying awareness for the procedure is thereby contributing to the growth of the Urolithiasis Management Devices market during the forecast period from 2024-2030.

Urolithiasis Management Devices Market Dynamics:

The Urolithiasis Management Devices market is witnessing a growth in product demand owing to various reasons. The key factor includes the rising prevalence of urolithiasis across the globe.

According to the European Association of Urology 2019, the prevalence rates for urinary stones vary from 1% to 20%, and in the countries with a high standard of life such as Canada, Sweden, or the US, renal stones prevalence is significantly high (>10%).

As per the British Association of Urological Surgeons 2022, Kidney stones are common. Patients undergoing a CT scan have an 8% chance of having kidney stones and its incidence has been steadily increasing since the early 20th century. Moreover, 1 in 11 people (9%) will get stone symptoms during their lifetime. Men are affected slightly more often than women. Patients of all ages suffer from stones, but the peak age for a first stone is around the age of 45.

According to the National Kidney Foundation 2022, over half a million people go to emergency rooms for kidney stone problems every year.

Moreover, a rise in sedentary lifestyle such as excessive consumption of alcohol, less consumption of water could also lead to the development of kidney stones. In addition, the growing burden of obesity among the population, a high-risk factor for the development of renal calculi, due to sedentary lifestyles such as poor dietary habits and lack of physical activities could also contribute to the Urolithiasis Management Devices market growth.

As per the World Health Organization (WHO) 2022 data, there was around 650 million obese population worldwide in the year 2016. Also, according to various studies, obese people develop more uric acid stones and calcium oxalate stones.

Also, the aging population is more prone to the formation of kidney stones and an increased risk of end-stage renal failure. As per the World Population Prospects, 2019, there were 703 million older persons aged 65 or over in 2019 globally. Therefore, as the aging population increases, there will be more prevalence of urolithiasis, which will eventually boost the demand for Urolithiasis Management Devices which will drive the growth of the Global Urolithiasis Management Devices market.

However, certain factors such as the high cost of ureteroscope devices and the postoperative complications like blood loss during internal bleeding may be certain limiting factors of the Urolithiasis Management Devices market growth.

The outbreak of the COVID-19 pandemic caused a significant decrease in emergency department visits. Moreover, there was a delay in outpatient clinic appointments which pushed the need towards virtual or telephone clinics. Due to a lack of in-hospital beds, anesthesia or procedural slots, and healthcare professionals, these changes created a significant backlog in the treatment, thereby creating a negative impact on the Global Urolithiasis Management Devices market.

Urolithiasis Management Devices Market Segment Analysis:

Urolithiasis Management Devices Market By Type (Diagnostics [X-Ray, Computed Tomography, Ultrasound, Others], Treatment [Shock Wave Lithotripters {Intracorporeal, Extracorporeal}, Ureteroscopes {Semi-Rigid, Flexible}, Stone Retrieval Devices, Others], By End-User (Hospitals, Ambulatory Surgical Centers, Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the Treatment segment of the Urolithiasis Management Devices market, the Extracorporeal Shock Wave Lithotripters (ESWL) is estimated to hold a higher share in the Urolithiasis Management Devices market during the forecast period (2024-2030). This can be attributed to the specific features associated with these devices.

The large market share of this product segment can be attributed to the growing patient adoption of these devices and quick treatment. The main benefit of ESWL is that the treatment is totally non-invasive, as it does not involve any skin incisions or the use of any invasive surgical instruments to treat the stone. Instead, shock waves are utilized to shatter the stone into tiny fragments that flow through the ureter and out of the bladder.

It also has other advantages such as reduced pain, quick recovery time, and shorter hospital stays. This treatment method is chosen by a majority of the patient and physician population.

ESWL is suited for small stones as well as certain stones present in the upper portion of the ureter. Moreover, multiple stones can also be treated with ESWL. Therefore, it is expected that with such advantages offered by the Extracorporeal Shock Wave Lithotripsy Devices this technology is expected to increase its penetration in coming years, thus this will drive the segment to grow during the forecast period, which will have a positive impact on the overall Global Urolithiasis Management Devices Market growth.

Furthermore, Extracorporeal Shock Wave Lithotripsy Devices are gaining commercial acceptability, which also improves market penetration. All these advantages of these devices make physicians more inclined to use Extracorporeal Shock Wave Lithotripsy Devices.

Hence, all the above-mentioned factors are expected to drive the segment growth of the Urolithiasis Management Devices market.

North America is expected to dominate the overall Urolithiasis Management Devices Market:

Among all the regions, North America is expected to account for the largest share in the Global Urolithiasis Management Devices market. Factors such as the growing prevalence of stone formations causing urolithiasis and increased risk of end-stage renal disease among the population, rising product approvals are expected to aid in the growth of the North America Urolithiasis Management Devices Market.

As per the Canadian Urological Association guidelines 2022, globally, the prevalence of urolithiasis is steadily increasing, and though some regional variability exists, contemporary estimates report up to 10-12% of men and 7-8% of women now suffer from nephrolithiasis.

Moreover, according to the US Department of Health and Human Services 2022, end-stage renal disease (ESRD) is a significant public health problem in the United States and a major source of suffering and poor quality of life for those afflicted.

Another factor responsible for the growth of the Urolithiasis Management Devices market is the launch of new products in the region. For instance, in 2019, Dornier Medtech launched and announced the immediate availability of its new AXIS single-use digital flexible ureteroscope in the US.

In 2019, Shockwave Medical Inc. received breakthrough device designation for its intravascular lithotripsy (IVL) therapy, used for lithotripsy and was long used to eliminate kidney stones.

Thus, these factors are projected to contribute to the Urolithiasis Management Devices market during the forecasted period.

The rising adoption of Urolithiasis Management Devices in the country would result in the rising demand for treatments that make use of Urolithiasis Management Devices, which in turn would provide a conducive growth environment for the United States Urolithiasis Management Devices market as well as the North American region. Therefore, the interplay of various factors such as the presence of a large patient population, encouraging reimbursement policies as well as new product launches in the region is expected to boost the North America Urolithiasis Management Devices market during the forecast period.

Urolithiasis Management Devices Market Key Players:

Some of the key market players operating in the Urolithiasis Management Devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus, General Electric Company (GE Healthcare), ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMINSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

Recent Developmental Activities in the Urolithiasis Management Devices Market:

In March 2022, Boston Scientific acquired Lumenis in a USD 1.07 billion deal. With this acquisition, Boston Scientific has strengthened its product portfolio for Lithotripsy devices. This will further add to the growth of the Global Urolithiasis Management Devices market.

In March 2022, Dornier MedTech GmbH became the world's first integrated urology company to be certified by the European Union's Medical Device Regulation (MDR). Dornier achieved the certification for its Class IIb products: Dornier Delta® III, one of the most powerful lithotripters that utilize Dornier's Extracorporeal Shock Wave Lithotripsy (ESWL) technology; and the Dornier UIMS(TM), a state-of-the-art information management software providing enhanced imaging and efficiency to support clinicians in treating kidney stones.

In August 2020, Olympus Winter & Ibe GmbH received the US FDA approval for OES Elite Ureteroscopes and Accessories under regulatory class II for endoscopic observation and therapy in the ureters, urethra, and urinary bladder.

Key Takeaways from the Urolithiasis Management Devices Market Report Study

  • Market size analysis for current Urolithiasis Management Devices market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Urolithiasis Management Devices market.
  • Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
  • Key companies dominating the global Urolithiasis Management Devices market.
  • Various opportunities available for the other competitor in the Urolithiasis Management Devices market space.
  • What are the top performing segments in 2023? How these segments will perform in 2030.
  • Which is the top-performing regions and countries in the current Urolithiasis Management Devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Urolithiasis Management Devices market growth in the coming future?

Target Audience who can be benefited from this Urolithiasis Management Devices Market Report Study

  • Urolithiasis Management Devices products providers
  • Research organizations and consulting companies
  • Urolithiasis Management Devices-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Urolithiasis Management Devices
  • Various End-users who want to know more about the Urolithiasis Management Devices market and latest technological developments in the Urolithiasis Management Devices market.

Frequently Asked Questions for the Urolithiasis Management Devices Market:

1. What is Urolithiasis Management Devices?

Urolithiasis Management Devices are devices used to manage Kidney stones (also called renal calculi, nephrolithiasis, or urolithiasis) that form inside kidneys.

2. What is the market for Global Urolithiasis Management Devices?

The global urolithiasis management devices market was valued at USD 1,531.08 million in 2023, growing at a CAGR of 4.27% during the forecast period from 2024 to 2030 to reach USD 1,963.12 million by 2030.

3. What are the drivers for the Global Urolithiasis Management Devices Market?

The Urolithiasis Management Devices market is witnessing a positive market growth owing to the rising prevalence of urolithiasis or nephrolithiasis. In addition, sedentary lifestyle such as obesity which is a risk factor for the development of kidney stones, innovation in product design, increased risk of end-stage renal failure, growing geriatric population, and intensifying awareness for the procedure is thereby contributing to the growth of the Urolithiasis Management Devices market.

4. Who are the key players operating in the Global Urolithiasis Management Devices Market?

Some of the key market players operating in the Urolithiasis Management Devices market include Boston Scientific Corporation, EMS Urology, Advin Health Care, Inceler Medikal Co. Ltd., Walz Elektronik GmbH, DirexGroup, Medispec Ltd., Richard Wolf GmbH, STORZ MEDICAL AG, Olympus, General Electric Company (GE Healthcare), ESAOTE SPA, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., BK Medical Holding Company, Inc., Hitachi Medical Systems, Laborie, DRAMINSKI S. A., ACE Medical Devices Pvt. Ltd., Siemens Healthcare Private Limited, Vimex Sp. z o.o., and others.

5. Which region has the highest share in Urolithiasis Management Devices Market?

North America is expected to hold the highest share in the revenue in the Urolithiasis Management Devices market during the forecast period. Factors such as the growing prevalence of stone formations causing urolithiasis and increased risk of end-stage renal disease among the population, rising product approvals, are expected to aid in the growth of the North America Urolithiasis Management Devices Market in this region.

Table of Contents

1.Urolithiasis Management Devices Market Report Introduction

2.Urolithiasis Management Devices Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory and Patent Analysis

  • 3.1. The United States
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Urolithiasis Management Devices Market Key Factors Analysis

  • 4.1. Urolithiasis Management Devices Market Drivers
    • 4.1.1. The Rising Prevalence of Urolithiasis or Nephrolithiasis
    • 4.1.2. Sedentary Lifestyle as a Risk Factor for the Development of Kidney Stones
    • 4.1.3. Innovation in Product Design
    • 4.1.4. Increased Risk of End-Stage Renal Failure
    • 4.1.5. Growing Geriatric Population
  • 4.2. Urolithiasis Management Devices Market Restraints and Challenges
    • 4.2.1. The High Cost of Ureteroscope Devices
    • 4.2.2. The Postoperative Complications
  • 4.3. Urolithiasis Management Devices Market Opportunities
    • 4.3.1. Need For Advanced Devices
    • 4.3.2. Growing Opportunities in Single-Use Ureteroscope

5. Urolithiasis Management Devices Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Urolithiasis Management Devices Market

7. Urolithiasis Management Devices Market Layout

  • 7.1. By Type
    • 7.1.1. Diagnostics
      • 7.1.1.1. X-ray
      • 7.1.1.2. Computed Tomography
      • 7.1.1.3. Ultrasound
      • 7.1.1.4. Others
    • 7.1.2. Treatment
      • 7.1.2.1. Shock Wave Lithotripters
      • 7.1.2.1.1. Intracorporeal
      • 7.1.2.1.2. Extracorporeal
      • 7.1.2.2. Ureteroscopes
      • 7.1.2.2.1. Semi-Rigid
      • 7.1.2.2.2. Flexible
      • 7.1.2.3. Stone Retrieval Devices
      • 7.1.2.4. Others
  • 7.2. By End-User
    • 7.2.1. Hospitals
    • 7.2.2. Ambulatory Surgical Centers
    • 7.2.3. Others
  • 7.3. By Geography
    • 7.3.1. North America
      • 7.3.1.1. United States
      • 7.3.1.2. Canada
      • 7.3.1.3. Mexico
    • 7.3.2. Europe
      • 7.3.2.1. France
      • 7.3.2.2. Germany
      • 7.3.2.3. United Kingdom
      • 7.3.2.4. Italy
      • 7.3.2.5. Spain
      • 7.3.2.6. Russia
      • 7.3.2.7. Rest of Europe
    • 7.3.3. Asia-Pacific
      • 7.3.3.1. China
      • 7.3.3.2. Japan
      • 7.3.3.3. India
      • 7.3.3.4. Australia
      • 7.3.3.5. South Korea
      • 7.3.3.6. Rest of Asia Pacific
    • 7.3.4. Rest of the World (RoW)

8. Urolithiasis Management Devices Market Global Company Share Analysis - Key 3-5 Companies

9. Urolithiasis Management Devices Market Company and Product Profiles

  • 9.1. Boston Scientific Corporation
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. EMS Urology
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Advin Health Care
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Inceler Medikal Co. Ltd.
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. Walz Elektronik GmbH
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. DirexGroup
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Medispec Ltd.
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. Richard Wolf GmbH
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. STORZ MEDICAL AG
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Olympus
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. General Electric Company (GE Healthcare)
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. ESAOTE SPA
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. BK Medical Holding Company, Inc.
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. Hitachi Medical Systems
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Laborie
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. DRAMINSKI S. A.
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. ACE Medical Devices Pvt. Ltd.
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Siemens Healthcare Private Limited
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Vimex Sp. z o.o.
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us